CLDX News and Press, Celldex Therapeutics Inc.

- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks - - Greatly improved quality of life and reduced disease impact for patients with ColdU/SD at Week 20 - HAMPTON, N.J...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

2026-02-25 17:43:21 ET More on Celldex Celldex surges after completing enrollments in late-stage trials for lead asset Seeking Alpha’s Quant Rating on Celldex Historical earnings data for Celldex Financial information for Celldex Read the ful...

Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027 Phase 3 cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) ...

2026-02-25 12:14:26 ET More on Celldex Seeking Alpha’s Quant Rating on Celldex Historical earnings data for Celldex Financial information for Celldex Read the full article on Seeking Alpha For further details see: Celldex surges after compl...

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU Topline data expected Q4 2026 BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enroll...

HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD) have been acce...

2026-01-13 15:20:00 ET ... Read the full article on Seeking Alpha For further details see: MoneyShow's Best Investment Ideas For 2026: Part 3

No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient life Barzolvolimab is the only drug in development to demonstrate clinical benefit in patients in ColdU and SD in a large, randomized, placebo-controlled study--a...

2025-11-19 15:01:02 ET The last time I spoke about Enanta Pharmaceuticals, Inc. ( ENTA ) it was in a Seeking Alpha article entitled "Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change." I noted then that this company had failed to me...